Drug intelligence / Profile preview

PLZ4-Alexa 488

Development stage: Preclinical
Lead developer: University of California, Davis
Modality: Peptides

Overview

PLZ4-Alexa 488 is a diagnostic imaging agent consisting of the cyclic peptide PLZ4 conjugated to the fluorescent dye Alexa Fluor 488. PLZ4 was discovered through "one bead one compound" (OBOC) combinatorial library screening and exhibits high specificity for bladder urothelial carcinoma cells in both human and canine models. The Alexa 488 conjugate is primarily used for the detection of cancer cells in urine samples and for fluorescence-based imaging of bladder tumor sections. Research indicates that PLZ4 maintains its binding affinity in the presence of urine, making it a potential tool for non-invasive bladder cancer diagnosis and targeted delivery of other agents.

Other names: PLZ4-Alexa488PLZ-4-Alexa488PLZ 4-Alexa488

Targets

NECTIN4 (Nectin-4)

Beyond the preview

Go deeper on PLZ4-Alexa 488.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PLZ4-Alexa 488.

Explore the full profile